Literature DB >> 29589285

Hematologic Markers of Lung Metastasis in Stage IV Colorectal Cancer.

Mohammad Abu-Shawer1, Osama Abu-Shawer2, Mamoun Souleiman2, Mohammad Akkawi2, Osama Alshakhatreh2, Tamer Altamimi2, Amal Al-Omari3, Maysa Al-Hussaini4.   

Abstract

BACKGROUND: Many studies showed an association between absolute neutrophil count (ANC), absolute monocyte count (AMC), neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) with poor overall survival (OS) in patients with cancer. However, only a few studies were conducted to further investigate this association in colorectal cancer (CRC).
METHODS: Clinical data from 299 stage IV CRC patients treated at King Hussein Cancer Center from 2004 to 2012 have been retrospectively reviewed. We examined the association between ANC, AMC, MLR, PLR, and NLR with lung metastasis in stage IV CRC. Receiver Operating Characteristic (ROC) curve analysis was operated to determine the optimal NLR cutoff value. Univariate and multivariate analysis were performed.
RESULTS: The ROC value of 3.4 was determined as the cutoff value of NLR to study the association. Univariate and multivariate analysis showed that patients with high baseline NLR (≥ 3.4) had more baseline lung metastasis than patients with low NLR (< 3.4) (p = 0.0001, p = 0.0151, respectively). Also, baseline NLR correlated significantly with the presence of lymphovascular invasion (p = 0.001). In patients with no baseline lung metastasis, high post-treatment NLR was associated with consequent development of lung metastasis (p = 0.0227). Other markers including ANC, AMC, MLR, and PLR were significantly associated with lung metastasis at time of diagnosis (p = 0.0006, p = 0.0006, p = 0.0187, and p = 0.001, respectively).
CONCLUSION: Results are suggesting that different hematologic markers obtained from a cheap test (CBC) could potentially be used to predict the likelihood of lung metastasis in stage IV CRC. Prospective studies are needed to further assess the immune cells' role in tumor metastasis promotion.

Entities:  

Keywords:  Colorectal cancer; Lung metastasis; Neutrophil-lymphocyte ratio; Stage IV

Year:  2019        PMID: 29589285     DOI: 10.1007/s12029-018-0089-0

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  6 in total

1.  The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC).

Authors:  I Abuelbeh; O Abu-Shawer; M Abu-Shawer; M Alkderat; M Safi; A Alwazani; A Alkhatib; B Abu-Hussain; M Aladawi; S Ismail; T Altamimi; Taher Abu Hejleh
Journal:  Avicenna J Med       Date:  2022-07-03

2.  Hematological Indices of Distant Metastases and Prognostic Nomogram in Gastro-Pancreatic and Biliary Tract Cancers.

Authors:  Razan Mansour; Osama Abu-Shawer; Ali Lattouf; Hala Sultan; Maysa Al-Hussaini
Journal:  Cancer Manag Res       Date:  2020-10-08       Impact factor: 3.989

3.  Disclosure of medical errors: physicians' knowledge, attitudes and practices (KAP) in an oncology center.

Authors:  Razan Mansour; Khawlah Ammar; Amal Al-Tabba; Thalia Arawi; Asem Mansour; Maysa Al-Hussaini
Journal:  BMC Med Ethics       Date:  2020-08-20       Impact factor: 2.652

4.  Hematologic markers of distant metastases in gastric cancer.

Authors:  Osama Abu-Shawer; Mohammad Abu-Shawer; Ayman Haimour; Abdullah Alhouri; Ala'a Aldeen Alkhatib; Musaab Abki; Omar Alqaisi; Omar Hamdan; Rahaf Alsaqri; Saeed Ismail; Tamer Altamimi; Maysa Al-Hussaini
Journal:  J Gastrointest Oncol       Date:  2019-06

5.  The clinical potential of circulating immune cell counts in primary gastric lymphoma.

Authors:  Ayman Haimour; Osama Abu-Shawer; Mohammad Abu-Shawer; Ali Al-Taji; Tamer Altamimi; Razan Mansour; Justin Z Amarin; Hala Sultan; Maysa Al-Hussaini
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  The clinical value of peripheral immune cell counts in pancreatic cancer.

Authors:  Osama Abu-Shawer; Mohammad Abu-Shawer; Abdullah Shurman; Ali Lattouf; Ayman Haimour; Omar Hamdan; Razan Mansour; Tamer Altamimi; Maysa Al-Hussaini
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.